We have a diverse pipeline designed to make a meaningful difference for patients
Lonapegsomatropin (TransCon hGH) in Children with Growth Hormone Deficiency: Efficacy and Safety of up to 2 Years of Treatment
Presented at the PES 2021 Virtual Annual Meeting, April 2021.
A. K. Maniatis, U. M. Nadgir, P. Hofman, P. Saenger, E. D. Chertok, E. M. Aghajanova, W. Song, M. Mao, S. Chessler, A. Komirenko, M. Beckert, A. D. Shu, P. S. Thornton
Estimating the Weekly Average IGF-1 from a Single IGF-1 Sample in Children with GHD Treated with Lonapegsomatropin
Presented at the PES 2021 Virtual Annual Meeting, April 2021.
Z. Lin, Y. Su, S. Chessler, A. Komirenko, E. Dam Christoffersen, A. D. Shu
Continued Efficacy and Safety with up to 2 Years of Treatment with Lonapegsomatropin (TransCon™️ hGH) in Children with Growth Hormone Deficiency
Presented at the PENS 2021 Virtual National Conference, April 2021.
D. Campbell, K. Walsh, N. Marlen, W. Song, M. Mao, S. Chessler, A. Komirenko, M. Beckert, A. D. Shu
Efficacy and Safety of up to 2 Years of Treatment with TransCon hGH (lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children with Growth Hormone Deficiency
Presented at the ENDO 2021, March 2021.
A.K. Maniatis, S.J. Casella, U.M. Nadgir, P. Hofman, P. Saenger, E.D. Chertok, E.M. Aghajanova, W. Song, M. Mao, S. Chessler, A. Komirenko, M. Beckert, A.D. Shu, P.S. Thornton.
Design of the foresiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults with Growth Hormone Deficiency (GHD)
Presented at the ENDO 2021, March 2021.
M. Fleseriu, J.O.L. Jørgensen, K.C.J. Yuen, C. Höybye, M. Mao, J. Kang, W. Song, A. Komirenko, A.D. Shu, M. Beckert.
Economic Burden of Growth Hormone Deficiency in a US Pediatric Population
Presented at the ENDO 2021, March 2021.
P. Kaplowitz, J. Manjelievskaia, L. Lopez-Gonzalez, C.D. Morrow, P. Pitukcheewanont, A. Smith.
Treatment Experience of Children with Growth Hormone Deficiency in the Phase 3 fliGHt Trial: Switching from Daily Growth Hormone to Once-weekly TransCon hGH
Presented at the Pediatric Endocrinology Nursing Society (PENS) 2020 national conference (virtual)
November 2 – 5, 2020
D. Campbell, K. Walsh, C. Herz, L. Weber, N. Marlen, K. Kummer, L. Reys, J. Gianettoni, J. Peng, A.D. Shu
Introduction of a Novel GH Auto-Injector for Once-weekly Administration of TransCon hGH
Presented at the Pediatric Endocrinology Nursing Society (PENS) 2020 national conference (virtual)
November 2 – 5, 2020
K. Walsh, D. Campbell, J. Permuy, M. Henson, L. Rodriguez, B. Macchus, A. Shiver, S. Jensen, A. Shu
Phase 3 fliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-weekly TransCon hGH in Children with Growth Hormone Deficiency
Presented at the ENDO Online 2020 virtual meeting
June 8 – 22, 2020
A.K. Maniatis, U. Nadgir, P. Saenger, G. Mick, K.L. Reifschneider, M.J. Abuzzahab, L. Deeb, L.A. Fox, K.A. Woods, J.M. Peng, D.B. Karpf, A.D. Shu, W. Song, S.J. Casella, P.S. Thornton
Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children with Growth Hormone Deficiency: Interim Analysis from the enliGHten Long-Term Extension Trial
Abstract presented at the ENDO Online 2020 virtual meeting
June 8 – 22, 2020
A.K. Maniatis, S.J. Casella, U.M. Nadgir, G.J. Mick, P. Hofman, P. Saenger, E.D. Chertok, Warshauer, W. Song, J.M. Peng, A.S. Komirenko, A.D. Shu, M. Beckert, E.M. Aghajanova, P.S. Thornton
The Pivotal Phase 3 heiGHt Trial of Weekly TransCon hGH vs. Daily hGH in Treatment-Naive Subjects with Pediatric Growth Hormone Deficiency
Poster presented at the Pediatric Academic Societies/Pediatric Endocrine Society Annual Meeting (PAS/PES)
April 27 – 30, 2019 (Baltimore, MD)
A.K. Maniatis, P. Thornton, P. Hofman, E. Aghajanova, E. Chertok, M. Korpal-Szczyrska, E. Giorgadze, T. Kovalenko, A.D. Shu, D.B. Karpf, W. Song, M. Beckert, J.A. Leff
TransCon hGH as a Long-Acting Growth Hormone for the Treatment of Pediatric Growth Hormone Deficiency
Poster presented at the Pediatric Endocrinology Nursing Society (PENS) 2019 National Conference
April 25 – 28, 2019 (Long Beach, CA)
D.L. Campbell, K.J. Walsh, C. Herz, J.W. Permuy, D.B. Karpf, W. Song, M. Beckert, J.A. Leff, A.D. Shu
TransCon® Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Phase 3 heiGHt Trial
Presented at the Endocrine Society (ENDO) Annual Meeting and Expo
March 23 – 26, 2019 (New Orleans, LA)
P. Thornton, P. Hofman, A.K. Maniatis, E. Aghajanova, E. Chertok, M. Korpal-Szczyrska, E. Giorgadze, T. Kovalenko, A.D. Shu, D.B. Karpf, M. Beckert, J.A. Leff
Baseline Demographics of the TransCon Growth Hormone Phase 3 heiGHt Trial
Poster presented at the 57th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE)
September 27 – 29, 2018 (Athens, Greece)
M. Beckert, A. Shu, D.B. Karpf, A. Maniatis, Z. Lin, J. A. Leff
The Rationale and Design of TransCon GH
Poster presented at the 57th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE)
September 27 – 29, 2018 (Athens, Greece)
K. Sprogøe, A. Shu, M. Beckert, E. Mortensen, D.B. Karpf, J.A. Leff
Baseline Demographics of the TransCon Growth Hormone Phase 3 heiGHt Trial
Poster presented at the 9th International Congress of the Growth Hormone Research & IGF Societies (GRS)
September 14 – 17, 2018 (Seattle, WA)
A. Shu, M. Beckert, D.B. Karpf, Z. Lin, J. A. Leff
Baseline Demographics of the TransCon Growth Hormone Phase 3 heiGHt Trial
Poster presented at the Endocrine Society (ENDO) Annual Meeting and Expo
March 17 – 20, 2018 (Chicago, IL)
M. Beckert, D.B. Karpf, A. Shu, Z. Lin, J.A. Leff
User Driven Development of a New Device for Weekly Growth Hormone Administration in Pediatric Patients
Poster presented at the 10th International Meeting of Pediatric Endocrinology (IMPE)
September 14 – 17, 2017 (Washington, D.C.)
K.Sprogøe, S. Jensen, H. Egesborg, P.E. Fabricius, B. Sørensen, and S.V. Jacobsen
Development of a Long-Acting Growth Hormone (LAGH): Size Matters
Poster presented at the 10th International Meeting of Pediatric Endocrinology (IMPE)
September 14 – 17, 2017 (Washington, D.C.)
P. Saenger, D.B. Karpf, E. Mortensen, M. Beckert, K. Sprogøe, J. Leff
Design and Clinical Development of TransCon Growth Hormone for Growth Hormone Deficiency
Poster presented at the Endocrine Society (ENDO) Annual Meeting and Expo
April 1 – 4, 2017 (Orlando, FL)
M.Beckert, J.M. Mikkelsen, G.N. Rasmussen, H. Rau, K. Sprogøe, J.A. Leff
User Driven Development of a New Device for Weekly Growth Hormone Administration in Pediatric Patients
Poster presented at the Endocrine Society (ENDO) Annual Meeting and Expo
April 1 – 4, 2017 (Orlando, FL)
S. Jensen, H. Egesborg, P.E. Fabricius, B. Sørensen, S.V. Jacobsen
Design of a Bracketed Dosing Regimen for the Administration of TransCon hGH, a Once-Weekly Growth Hormone Product
Poster presented at the Endocrine Society (ENDO) Annual Meeting and Expo
April 1 – 4, 2017 (Orlando, FL)
K. Sprogøe, S. Jensen, H. Egesborg
Design and Rationale for the heiGHt Trial, a Phase 3 TransCon hGH Study in Children with Growth Hormone Deficiency
Poster presented at the Endocrine Society (ENDO) Annual Meeting and Expo
April 1 – 4, 2017 (Orlando, FL)
M. Beckert, D.B. Karpf, E. Mortensen, J. Mardell, E.D. Christoffersen, J.A. Leff
The Rationale and Design of TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency
Endocr Connect. 2017,6(8):R171–R181.
K. Sprogøe, E. Mortensen, D.B. Karpf, J.A. Leff
A Randomized Phase 2 Study of Long-Acting TransCon GH vs. Daily GH in Childhood GH Deficiency
J Clin Endocrinol Metab. 2017, 102(5): 1673–1682; doi: 10.1210/jc.2016-3776.
P. Chatelain, O. Malievsky, K. Radziuk, G. Senatorova, M. Abdou, E. Vlachopapadopolou, Y. Skorodok, V. Peterkova, J. Leff, M. Beckert, the TransCon GH Working Group. J Clin Endocrinol Metab
A Phase 2 Trial of Long-acting TransCon Growth Hormone in Adult GH Deficiency
Endocr Connect. 2017,6(3):129–138.
C. Höybye, A.F.H. Pfeiffer, D. Ferone, J.S. Christiansen, D. Gilfoyle, E.D. Christoffersen, E. Mortensen, J.A. Leff, M. Beckert
A First-in-Man Phase 1 Trial for Long-Acting TransCon Growth Hormone
Epub December 5, 2017
D. Gilfoyle, E. Mortensen, E.D. Christoffersen, J.A. Leff, M. Beckert. Growth Horm IGF Res. 2018
Pediatric Phase 2 Data Demonstrate That TransCon hGH has an Anti-hGH Immunogenic Profile that Is Comparable to Daily hGH
Poster presented at 55th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE)
September 10 – 12, 2016 (Paris, France)
D. Gilfoyle, S. Pihl, P. Chatelain, M. Beckert
A Six-Month Safety and Efficacy Study of TransCon hGH Compared to Daily hGH in Prepubertal Children with Growth Hormone Deficiency (GHD)
Poster presented at 55th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE)
September 10 – 12, 2016 (Paris, France)
P. Chatelain, O. Malievsky, K. Radziuk, G. Senatorova, M. Beckert
Design and Clinical Development of TransCon Growth Hormone for Growth Hormone Deficiency
Poster presented at 55th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE)
September 10 – 12, 2016 (Paris, France)
M. Beckert, D. Gilfoyle, J.M. Mikkelsen, et al.
Pharmacokinetic Modelling Predicts Native hGH Levels Following Administration of a Sustained-Release Prodrug, TransCon hGH, to Children With GHD
Poster presented at 55th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE)
September 10 – 12, 2016 (Paris, France)
K. Sprogøe, M. Beckert, E.D. Christoffersen, D. Gilfoyle, T. Wegge
If you are a healthcare provider who would like more information, please contact us.